More articles from Commentary

You have access
Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach
Stephen E. Langille

PDA Journal of Pharmaceutical Science and Technology May 2020, 74 (3) 359-366; DOI: https://doi.org/10.5731/pdajpst.2019.010462
You have access
Disinfectant Efficacy: Understanding the Expectations and How to Design Effective Studies That Include Leveraging Multi-Site Data to Drive an Efficient Program
Derek Willison-Parry, Stephen Yang, Ren-Yo Forng, Tim Cirbo, Aileen Mcmeel, Brian Kiler and Christopher Phillion

PDA Journal of Pharmaceutical Science and Technology March 2020, 74 (2) 249-263; DOI: https://doi.org/10.5731/pdajpst.2018.009662
You have access
Advancing Biologics Development Programs with Legacy Cell Lines: Advantages and Limitations of Genetic Testing for Addressing Clonality Concerns Prior to Availability of Late Stage Process and Product Consistency Data
Paul Wu, Taymar Hartman, Louise Almond, Jennitte Stevens, John Thrift, Juhi Ojha, Christina Alves, David Shaw, Michael W. Laird, Robyn Emmins, Yuan Zhu, Ren Liu, Zhimei Du, Rolf Koehler, Thomas Jostock, Karin Anderson, Chris Campbell and Howard Clarke

PDA Journal of Pharmaceutical Science and Technology March 2020, 74 (2) 264-274; DOI: https://doi.org/10.5731/pdajpst.2018.009316
You have access
Managing Excipient Supplier Name and Address Changes in the Pharmaceutical Quality System
Richard Rolke, Emma Ramnarine, Anders Vinther and Anil Sawant

PDA Journal of Pharmaceutical Science and Technology March 2020, 74 (2) 286-288; DOI: https://doi.org/10.5731/pdajpst.2019.011239
You have access
Identification and Quantitation Classifications for Extractables and Leachables
Dennis Jenke

PDA Journal of Pharmaceutical Science and Technology March 2020, 74 (2) 275-285; DOI: https://doi.org/10.5731/pdajpst.2019.010538
You have access
The Bugs Don't Lie
James P. Agalloco

PDA Journal of Pharmaceutical Science and Technology November 2019, 73 (6) 615-621; DOI: https://doi.org/10.5731/pdajpst.2019.009894
You have access
Biopharmaceutical Industry Practices for Sequence Variant Analyses of Recombinant Protein Therapeutics
John Valliere-Douglass, Lisa Marzilli, Aparna Deora, Zhimei Du, Luhong He, Sampath R. Kumar, Yan-Hui Liu, Hans-Martin Mueller, Charles Nwosu, John Stults, Yan Wang, Sam Yaghmour and Yizhou Zhou

PDA Journal of Pharmaceutical Science and Technology November 2019, 73 (6) 622-634; DOI: https://doi.org/10.5731/pdajpst.2019.010009
You have access
Fidelity to Science & Correct Scientific Vocabulary—Microbial Control Versus Contamination Control
Edward C. Tidswell, Radha Tirumalai and David Hussong

PDA Journal of Pharmaceutical Science and Technology September 2019, 73 (5) 510-516; DOI: https://doi.org/10.5731/pdajpst.2018.009795
You have access
What Does It Really Look Like to Properly Address a “Human Error Problem” in Biopharma? The Human Performance Blue-Sky Description That Will Help Improve Industry Performance
Clifford Berry, Brian Chviruk, Danny Hernandez, Matt Beaugard, Kelly B. Stevens, Joe Polizzotto, Lene Bjerregaard and Daan Purbrick

PDA Journal of Pharmaceutical Science and Technology July 2019, 73 (4) 391-400; DOI: https://doi.org/10.5731/pdajpst.2018.009621
You have access
How One Might Experimentally Determine if Container Closure Systems and Their Components and Materials of Construction Contribute Elemental Impurities To Packaged Pharmaceutical Drug Products
Dennis Jenke

PDA Journal of Pharmaceutical Science and Technology March 2019, 73 (2) 181-190; DOI: https://doi.org/10.5731/pdajpst.2018.008938

Main menu

User menu

Search

More articles from Commentary

Pages

Readers

Author/Reviewer Information

Parenteral Drug Association, Inc.